Bemfivastatin hemicalcium
Product Specifications
CAS Number
805241-64-9
Target
Others, HMG-CoA Reductase
Related Pathways
Metabolism, Others
Bioactivity
Bemfivastatin hemicalcium (PPD 10558), an orally active HMG-CoA reductase inhibitor, serves as a lipid-lowering agent. It amplifies liver extract activity and exhibits no-observed adverse effect levels (NOAEL) at dosages of ≥320 mg/kg/d for rat developmental toxicity, ≥12.5 mg/kg/d for rabbit maternal toxicity, and ≥25 mg/kg/d for rabbit developmental toxicity. This compound is utilized in research concerning hypercholesterolemic myalgia in patients intolerant to statins.
Smiles
[O-]C(C[C@H](O)C[C@H](O)CCN1C(C2=CC=C(C=C2)F)=C(C3=CC=CC=C3)C(C(NC4=CC=C(C=C4)CO)=O)=C1C(C)C)=O.[Ca+2]
Molecular Formula
C34H36FN2O6.1/2Ca
Molecular Weight
607.67
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6416239-01 0.1 mL
ERF3B (Eukaryotic Peptide Chain Release Factor GTP-Binding Subunit ERF3B, GSPT2, G1 To S Phase Transition 2, GST2) (MaxLight 490)
Sign In for Pricing
View Details MBS6416239-02 5x 0.1 mL
ERF3B (Eukaryotic Peptide Chain Release Factor GTP-Binding Subunit ERF3B, GSPT2, G1 To S Phase Transition 2, GST2) (MaxLight 490)
Sign In for Pricing
View Details